COVID-19 Viral Load Rebound Can Occur After VV116, Nirmatrelvir-Ritonavir
By Elana Gotkine HealthDay Reporter
WEDNESDAY, March 20, 2024 -- For patients with mild-to-moderate COVID-19, viral load rebound and symptom rebound can occur after a standard five-day course of treatment with VV116 or nirmatrelvir-ritonavir, according to a study published online March 13 in JAMA Network Open.
Zhitao Yang, M.D., from Ruijin Hospital in Shanghai, and colleagues conducted a randomized clinical trial involving adults with mild-to-moderate COVID-19 and within five days of severe acute respiratory syndrome coronavirus 2 infection. Participants were randomly allocated to receive VV116 or nirmatrelvir-ritonavir (165 and 180 patients, respectively) for five days.
The researchers found that viral load rebound occurred in 20.0 and 21.7 percent of patients in the VV116 and nirmatrelvir-ritonavir groups, respectively. Symptom rebound occurred in 25.6 and 24.5 percent of patients in the VV116 and nirmatrelvir-ritonavir groups, respectively. For 24 rebound cases, viral whole-genome sequencing showed the same lineage at baseline and viral load rebound.
"Effective treatment options in addition to the drug per se, especially the potential prolongation of treatment duration, as well as the interplay of viral infection, host immunity, and antiviral treatment in the process of rebound, warrant investigation in future studies," the authors write.
VV116 and nirmatrelvir-ritonavir tablets were provided by the Shanghai Junshi Biosciences.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Further Support and Information on COVID-19
Read this next
Mortality Higher for COVID-19 Hospitalization Than for Flu in 2023/2024 Season
WEDNESDAY, May 22, 2024 -- In fall/winter 2023/2024, the risk for death in patients hospitalized for COVID-19 was greater than the risk for death in patients hospitalized for...
Global Life Expectancy, Disease Burden Set to Keep Improving
WEDNESDAY, May 22, 2024 -- Life expectancy and age-standardized disease burden are expected to continue improving between 2022 and 2050, according to the Global Burden of Disease...
Long COVID Definitions, Care Models Are Evolving
MONDAY, May 20, 2024 -- Definitions of long COVID and care models are evolving, but considerable variability is seen in these models, according to a review published online May 21...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.